Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
Ebiomedicine|May 24, 2016
Stroke, Migraine and Triptans: From Bedside to BenchEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Clinical Pharmacokinetics|February 28, 2015
Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus"Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
The Lancet. Oncology|December 1, 2022
QT prolongation with anticancer drugs: a multimodal issueEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Clinical Pharmacology and Therapeutics|April 1, 2025
Chat GPT and the Challenges to Detect Potential Drug-Drug Interactions Related to QT ProlongationEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Brain, Behavior, and Immunity|November 23, 2019
Reduced neuropsychiatric events as "beneficial reactions" to drugs: Seek associations with cautionEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Recenti Progressi in Medicina|May 25, 2023
[Interactions between drugs, environment and health: a new challenge for epidemiology.]Ursula Kirchmayer, Elisabetta Poluzzi, Francesco Barone-Adesi
British Journal of Clinical Pharmacology|May 24, 2023
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug-drug interactions in clinical practiceEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Drug Safety|August 27, 2020
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceEmanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Cephalalgia : an International Journal of Headache|August 8, 2013
Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System databaseGiuseppe Roberto, Carlo Piccinni, Roberto D'Alessandro, et al.
Frontiers in Pharmacology|July 12, 2023
Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiologyYoshihiro Noguchi, Miao Yan, Satoshi Yokoyama, et al.
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
Ebiomedicine|May 24, 2016
Stroke, Migraine and Triptans: From Bedside to BenchEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Clinical Pharmacokinetics|February 28, 2015
Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus"Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
The Lancet. Oncology|December 1, 2022
QT prolongation with anticancer drugs: a multimodal issueEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Clinical Pharmacology and Therapeutics|April 1, 2025
Chat GPT and the Challenges to Detect Potential Drug-Drug Interactions Related to QT ProlongationEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Brain, Behavior, and Immunity|November 23, 2019
Reduced neuropsychiatric events as "beneficial reactions" to drugs: Seek associations with cautionEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Recenti Progressi in Medicina|May 25, 2023
[Interactions between drugs, environment and health: a new challenge for epidemiology.]Ursula Kirchmayer, Elisabetta Poluzzi, Francesco Barone-Adesi
British Journal of Clinical Pharmacology|May 24, 2023
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug-drug interactions in clinical practiceEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Drug Safety|August 27, 2020
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceEmanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Cephalalgia : an International Journal of Headache|August 8, 2013
Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System databaseGiuseppe Roberto, Carlo Piccinni, Roberto D'Alessandro, et al.
Frontiers in Pharmacology|July 12, 2023
Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiologyYoshihiro Noguchi, Miao Yan, Satoshi Yokoyama, et al.
Pageof 19